Mark Hillman's BIIB Position Overview
Mark Hillman (via Hillman Capital Management, Inc.) currently holds 30,516 shares of Biogen Inc. (BIIB) worth $5.37 M, representing 3.38% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Mark Hillman has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 15,488 shares. Largest reduction occurred in Q3 2022, reducing 11,265 shares.
Analysis based on 13F filings available since 2013 Q2
Mark Hillman's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Mark Hillman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -7,838 | Reduce 20.44% | 30,516 | $175.99 |
| Q3 2025 | -3,618 | Reduce 8.62% | 38,354 | $140.08 |
| Q2 2025 | -2,053 | Reduce 4.66% | 41,972 | $125.59 |
| Q1 2025 | +959 | Add 2.23% | 44,025 | $136.84 |
| Q4 2024 | +7,813 | Add 22.16% | 43,066 | $152.92 |
| Q3 2024 | -701 | Reduce 1.95% | 35,253 | $193.84 |
| Q2 2024 | +162 | Add 0.45% | 35,954 | $231.82 |
| Q1 2024 | +1,316 | Add 3.82% | 35,792 | $215.63 |
| Q4 2023 | +170 | Add 0.50% | 34,476 | $258.77 |
| Q3 2023 | +4,895 | Add 16.64% | 34,306 | $257.01 |
| Q2 2023 | -125 | Reduce 0.42% | 29,411 | $284.85 |
| Q1 2023 | -540 | Reduce 1.80% | 29,536 | $278.03 |
| Q4 2022 | -1,678 | Reduce 5.28% | 30,076 | $276.92 |
| Q3 2022 | -11,265 | Reduce 26.19% | 31,754 | $267.02 |
| Q2 2022 | +340 | Add 0.80% | 43,019 | $203.96 |
| Q1 2022 | +15,488 | Add 56.96% | 42,679 | $210.60 |
| Q4 2021 | -1,098 | Reduce 3.88% | 27,191 | $239.90 |
| Q3 2021 | +1,050 | Add 3.85% | 28,289 | $282.97 |
| Q2 2021 | -50 | Reduce 0.18% | 27,239 | $346.27 |
| Q1 2021 | +7,360 | Add 36.93% | 27,289 | $279.75 |
| Q4 2020 | +292 | Add 1.49% | 19,929 | $244.87 |
| Q3 2020 | +3,391 | Add 20.87% | 19,637 | $283.70 |
| Q2 2020 | -134 | Reduce 0.82% | 16,246 | $267.57 |
| Q1 2020 | -1,734 | Reduce 9.57% | 16,380 | $316.36 |
| Q4 2019 | +18,115 | Add 0.00% | 18,114 | $296.73 |
Mark Hillman's Biogen Investment FAQs
Mark Hillman first purchased Biogen Inc. (BIIB) in Q4 2019, acquiring 18,114 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mark Hillman has held Biogen Inc. (BIIB) for 25 quarters since Q4 2019.
Mark Hillman's largest addition to Biogen Inc. (BIIB) was in Q4 2019, adding 18,114 shares worth $5.38 M.
According to the latest 13F filing for Q4 2025, Mark Hillman's firm, Hillman Capital Management, Inc., owns 30,516 shares of Biogen Inc. (BIIB), valued at approximately $5.37 M.
As of the Q4 2025 filing, Biogen Inc. (BIIB) represents approximately 3.38% of Mark Hillman's publicly disclosed stock portfolio, making it one of their key holdings.
Mark Hillman's peak holding in Biogen Inc. (BIIB) was 44,025 shares, as reported at the end of Q1 2025.